Alprazolam
The active substance of Xanax is alprazolam. It belongs to a group of medicines called benzodiazepines (anxiolytic medicines). Xanax is indicated for the treatment of symptoms of anxiety disorders in adults, only in situations where the symptoms are severe, prevent normal functioning, or are very troublesome for the patient. This medicine is intended for short-term use only.
Xanax should not be taken by children and adolescents under 18 years of age.
Before starting Xanax, the patient should discuss the following with their doctor:
Episodes of hypomania and mania have been reported in association with Xanax in patients with depression. Before planned surgery, the doctor should be informed about the use of Xanax.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before taking this medicine. Xanax is not recommended during pregnancy. If the medicine is taken during pregnancy or if the patient becomes pregnant while taking alprazolam, they should be examined for potential fetal risk. If the medicine is necessary in the last trimester of pregnancy, high doses should be avoided and the newborn should be monitored. Benzodiazepines pass into breast milk in small amounts. Xanax should not be taken during breastfeeding.
Xanax causes impairment of psychophysical fitness. Before taking Xanax, the patient should familiarize themselves with local traffic laws. While taking Xanax, the patient should not drive vehicles or operate machines.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
Each tablet of this medicine contains 0.11 mg of sodium benzoate.
This medicine should always be taken according to the doctor's instructions. In case of doubts, the patient should consult their doctor or pharmacist. Xanax is available in the following doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg. Treatment should be as short as possible. The doctor should frequently assess the patient's condition and the need to extend treatment, especially if the severity of the symptoms decreases and may not require pharmacological treatment. The total treatment time should not exceed 2-4 weeks. Long-term treatment is not recommended. When starting treatment, the doctor will inform the patient about the limited duration of therapy, the gradual reduction of the dose during withdrawal, and the possibility of withdrawal reactions. During the use of benzodiazepines, including Xanax, dependence and emotional or physical dependence may develop. This risk may increase with the dose and duration of treatment, so the smallest effective dose should be used for the shortest possible time, and the need for continued treatment should be frequently assessed with the doctor. Recommended dose The dose is determined by the doctor based on the severity of symptoms and the patient's individual response to treatment. If severe side effects occur after the initial dose, the doctor may decide to reduce the dose. Symptomatic treatment of anxiety disorders The recommended initial dose is 0.25 mg or 0.5 mg three times a day. The doctor may decide to increase the dose, depending on the patient's needs, up to a maximum daily dose of 4 mg, divided into smaller doses, taken throughout the day.
Xanax should not be taken by children and adolescents under 18 years of age.
Use in patients with severe liver failure is contraindicated.
The recommended initial dose is 0.25 mg two or three times a day. If necessary, the doctor may decide to gradually increase the dose, depending on the patient's tolerance to the medicine. If side effects occur, the doctor will decide to reduce the initial dose.
Taking a higher than recommended dose of Xanax may cause: ataxia (motor incoordination), drowsiness, speech disorders, coma, and respiratory depression. If worrying symptoms occur, the patient should immediately consult their doctor.
A double dose should not be taken to make up for a missed dose.
The patient should not stop taking Xanax on their own. Since the treatment is symptomatic, after its discontinuation, the disease symptoms may return. The doctor will decide to gradually reduce the dose. If the patient has any further doubts about the use of this medicine, they should consult their doctor.
Like all medicines, Xanax can cause side effects, although not everybody gets them. If any of the following side effects persist or are troublesome, the patient should inform their doctor. The occurrence of some side effects depends entirely on the patient's individual susceptibility and the dose of the medicine. Side effects are usually observed at the beginning of therapy and disappear as treatment continues or when the dose is reduced. Frequency of side effects observed in clinical trials and after the medicine was placed on the market:
Additionally, especially in patients taking other psychotropic medicines, with mental disorders, or abusing alcohol, a paradoxical reaction may occur with symptoms such as anxiety. Other side effects have been observed rarely or very rarely: motor disorders, epilepsy, psychotic symptoms, a feeling of changed self, agranulocytosis (a significant decrease in granulocyte count), allergic reactions, or anaphylaxis (severe allergic reactions). Benzodiazepines may cause physical and psychological dependence. If physical dependence occurs, abrupt discontinuation of Xanax may cause withdrawal symptoms: headache, muscle pain, increased anxiety, tension, excitement, disorientation, irritability, changed perception of the environment or oneself, impaired hearing, stiffness, and paresthesia of the limbs, hypersensitivity to light, noise, and touch, hallucinations, and seizures. These symptoms are usually more severe in patients treated for a long time, with high doses of benzodiazepines, and in the case of abrupt or rapid discontinuation of the medicine.
If any side effects occur, including any side effects not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored in a place invisible and inaccessible to children. Do not store above 25°C. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the given month. Medicines should not be disposed of via wastewater or household waste containers. The patient should ask their pharmacist how to dispose of medicines that are no longer used. This will help protect the environment.
Xanax, 0.25 mg, is a white, elliptical-oval tablet, scored, with "Upjohn 29" on one side and a score line on the other side. The package contains 30, 50, or 100 tablets in PVC/PVDC-Aluminum blisters in a cardboard box. For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
UPJOHN HELLAS LTD., 253-255, Messoghion Ave, Neo Psychiko 154 51, Greece
Pfizer Italia S.r.l., Localita Marino del Tronto, 63100 – Ascoli Piceno (AP), Italy Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Ireland
InPharm Sp. z o.o., ul. Strumykowa 28/11, 03-138 Warsaw
InPharm Sp. z o.o. Services sp. k., ul. Chełmżyńska 249, 04-458 Warsaw Greek marketing authorization number: 23875/26-06-1995Parallel import authorization number: 3/18Date of leaflet approval: 20.12.2022[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.